Coherus appoints Dr. Lee Newcomer to board; Dr. James Healy resigns

Coherus Oncology, Inc.

Appointed Dr. Lee Newcomer to Board effective Feb 2; receives option for 54k shares plus $50k annual retainer.
Newcomer is former UnitedHealth CMO, brings oncology and payer expertise to board.
Director James Healy resigned Feb 4; departure not due to any disagreement.
Mark Stolper reclassified from Class III to Class II to equalize board class sizes.
Board expanded to 7 members; now 2 directors per class.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lee N. Newcomer

Director

CHRS · Coherus Oncology, Inc.

Effective: 2022-02-02
Filed: February 7, 2022, 6:59 PM ET

On February 2, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”) increased the size of the Board from six directors to seven directors and appointed Dr. Lee N. Newcomer to fill the vacancy created by such increase.

Departed

James I. Healy

Director

CHRS · Coherus Oncology, Inc.

Effective: 2022-02-04
Filed: February 7, 2022, 6:59 PM ET

On February 4, 2022, James I. Healy, M.D., Ph.D. resigned from the Board of the Company, effective immediately upon notice of his resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lee N. Newcomer was appointed as Director at Coherus Oncology, Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 2, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”) increased the size of the Board from six directors to seven directors and appointed Dr. Lee N. Newcomer to fill the vacancy created by such increase.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James I. Healy resigned as Director at Coherus Oncology, Inc..

Action: resigned
Role: Director

Exact text from the filing

On February 4, 2022, James I. Healy, M.D., Ph.D. resigned from the Board of the Company, effective immediately upon notice of his resignation.

View on SEC.gov

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-029787

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.